Drug Profile
Research programme: CNS disorder therapeutics - Taisho/Merck
Alternative Names: MGS 0008; MGS 0028; MGS 0210Latest Information Update: 23 Mar 2010
Price :
$50
*
At a glance
- Originator Taisho Pharmaceutical
- Developer Merck & Co; Taisho Pharmaceutical
- Class Dicarboxylic acids
- Mechanism of Action Metabotropic glutamate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anxiety disorders; Major depressive disorder; Schizophrenia
Most Recent Events
- 31 Oct 2006 Preclinical trials in Anxiety disorders in Japan (Intraperitoneal)
- 31 Oct 2006 Preclinical trials in Depression in Japan (Intraperitoneal, PO)
- 31 Oct 2006 Data presented at the 36th Annual Meeting of the Society for Neuroscience (SfN-2006) have been added to the Affective Disorders and Anxiety Disorders pharmacodynamics sections and the pharmacokinetics section